Beyond drugs and surgery: changing medicine as we know it

As a company committed to proving the promise of regenerative medicine, GID continues to evaluate applications of its SVF-2 cellular implant platform clinically. One such application is the treatment of rheumatoid arthritis (RA) in the hands.

RA affects about 1.5 million people in the United States—more than three times as many women as men. It can cause occasional or constant pain and swelling in the feet, ankles, knees, elbows, wrists, and—most commonly—hands, making everyday tasks like opening a jar, peeling a banana, writing, or tying a shoe extremely difficult.

We conducted a first safety and feasibility study on the treatment of RA of the hands with the SVF-2 cellular implant technology. The results were published in CellR41.

The study looked at five female patients with symptomatic rheumatoid arthritis of the hands lasting more than one year. Each patient was asked to complete an assessment before the cellular implant and at three months and six months after treatment. Patients recorded their pain, stiffness, and difficulty with activities using functional hand score (FHS) and visual analog scale (VAS) assessments. A dynamometer was also used to assess grip strength in kg.

As soon as two weeks after the procedure, all patients recorded significant improvement in pain, stiffness, and quality of function, in all treated hands. At six months the patients had an average of 92% improvement in FHS score. The VAS scores showed similarly remarkable improvement, with a 91% reduction in pain six months following the implant. In the same time, grip strength improved by an average of 59%.

This study was initial confirmation of the potential of the SVF-2 technology to safely and feasibly treat RA. More studies are underway to further establish the safety and efficacy of the SVF-2 technology for treatment of rheumatoid arthritis.

Click here to read the complete study as published in CellR4.

  1. Carstens M, Montenegro J, Gomez A, Correa D. Adipose-derived stromal vascular fraction (SVF) cells in the treatment of rheumatoid arthritis of the hand. CellR4 2018; 6(3): e2533:1-10